Opinion|Videos|January 17, 2025
Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024
Author(s)Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Z. Usmani, MD, MBA, FACP, discusses how the iMMagine-1 trial, presented at ASH 2024, evaluated the novel chimeric antigen receptor (CAR) T-cell therapy anitocabtagene autoleucel, detailing its study objectives, design, and methodology as well as the promising results that highlight its potential to advance treatment options for multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the novel CAR T-cell therapy anitocabtagene autoleucel, as studied in the iMMagine-1 trial and presented at ASH 2024.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
New Regulations on PBMs Become Law: What This Means for Pharmacies Nationwide—A Q&A With Jesse Dresser, Esq
2
Senate Democrats Outline Drug Pricing Agenda to Cut Patient Costs
3
Increased Payments to Medicare Advantage Plans for Dually Eligible Beneficiaries
4
ACOs Improve Primary, Preventive Care Delivery for Medicare Beneficiaries
5
